As previously noted [9], JAK2/CALR/MPL/TN mutational status did not appear to impact overall or leukemia-free survival in our current ET patient cohort while MPL mutation was associated with a significantly higher rate of progression to myelofibrosis, as per previous reports [21, 22]. This evidence concerns the gene JAK2 and myelofibrosis.